Abstract 784P
Background
Choriocarcinoma (CC) is a rare and highly aggressive cancer that exists in both the gestational (GCC) and non-gestational (NGCC) forms. Our research focused on comparing clinical outcomes, response to therapy, and prognostic determinants between these subtypes.
Methods
We analyzed data from the SEER database of patients diagnosed with CC between 2000 and 2020. Patients who were not diagnosed based on histology, previous history of cancer or other concurrent malignancies, or unknown data were excluded. The chi-square test were used for clinical features comparison. Kaplan-Meier estimation, log-rank tests, and Cox regression analyses were used to identify prognostic factors for overall survival (OS) and cancer specific survival (CSS). A nomogram was developed to predict 5-year OS, and a calibration curve was plotted to evaluate the agreement between the actual (observed) outcomes and expected probabilities.
Results
Of the 719 patients studied, 520 had GCC, and 200 had NGCC. Younger individuals were more common in the GCC. Additionally, a higher percentage of patients with NGCC were married (63.0% vs. 52.6%). AJCC stage distribution also differed; 47.4% of GCC patients were at stage I compared to 6.0% of NGCC patients. The surgery rates were higher in the NGCC group (79.5% vs. 60.9%). Patients with GCC had better OS than those with NGCC (93% vs. 71.2%, p = 0.001). CSS rates were 66.8% for NGCC and 65.2% for GCC (p = 0.001).
We developed a prognostic nomogram that integrated significant variables from multivariate analysis. For GCC, the model assigned the highest weight to radiation, followed by metastasis, and marital status. The AUC was 0.711 (95% CI: 0.64–0.79), and the calibration curves exhibited a mean error of 0.015. The NGCC model assigned the highest weights to metastasis, chemotherapy, and age. The AUC was 0.837 (95% CI, 0.77–0.9), and the calibration curve for 5-year survival demonstrated a mean error of 0.01.
Conclusions
Our study highlights the significant clinical and survival differences between GCC and NGCC patients. We developed prognostic nomograms tailored to each subtype to enhance prediction and support personalized management.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
793TiP - A phase III, randomized, open-label, multicenter study of sacituzumab tirumotecan (sac-TMT) monotherapy vs treatment of physician’s choice chemotherapy in patients with endometrial cancer who have received prior chemotherapy and immunotherapy: ENGOT-en23/GOG-3095/MK-2870-005
Presenter: Domenica Lorusso
Session: Poster session 02
795TiP - A first-in-human phase I study of LY4170156, an antibody-drug conjugate targeting folate receptor α (FRα)-expressing advanced solid tumors
Presenter: Isabelle Ray-Coquard
Session: Poster session 02
796TiP - Rationale and study design of the KOV-HIPEC-04: A phase III randomized controlled trial in primary stage three and four ovarian cancer after interval cytoreductive surgery (FOCUS)
Presenter: Junhwan Kim
Session: Poster session 02
797TiP - Tislelizumab combined with chemotherapy as neoadjuvant treatment for advanced endometrial cancer: A prospective, single-arm, open-label clinical study
Presenter: Zheng Hu
Session: Poster session 02
798TiP - Stereotactic radiotherapy alone or followed by niraparib for oligometastases or oligoprogression in ovarian cancer following PARP inhibitor therapy: SOPRANO trial
Presenter: Susana Banerjee
Session: Poster session 02
856P - Safety of neoadjuvant PARP inhibitor and immunotherapy in locally advanced HPV-negative head and neck squamous cell carcinoma (PRIME H&N Study)
Presenter: Luigi Lorini
Session: Poster session 02
857P - Safety and efficacy of neoadjuvant immunochemotherapy in patients with locally advanced head and neck squamous cell carcinoma: A prospective single-arm clinical trial
Presenter: Jing Yan
Session: Poster session 02
Resources:
Abstract
858P - Preoperative neoadjuvant chemoimmunotherapy for locally advanced head and neck squamous cell carcinoma patients: A prospective, single-arm, phase II clinical study
Presenter: Ping Han
Session: Poster session 02